Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerb...
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
To evaluate the efficacy and safety of Risperidone ISM
®
against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 2018 (NCT03160521). Eligible patients received once-monthly intramuscular injections of Risperidone ISM
Alternative Titles
Full title
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_485f9847ecae4df6ad9a103f3ac27f37
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_485f9847ecae4df6ad9a103f3ac27f37
Other Identifiers
ISSN
2334-265X
E-ISSN
2334-265X
DOI
10.1038/s41537-020-00127-y
